Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers

Journal of Clinical Psychopharmacology

Volumn 22, Issue 4, 2002, Pages 366-370

  Penzak, Scott R ^a,b   Hon, Yuen Yi ^a   Lawhorn, Walter D ^a   Shirley, Kara L ^a   Spratlin, Vicky ^a   Jann, Michael W ^a  

^a MERCER UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; OLANZAPINE; RITONAVIR;

ADULT; ARTICLE; BLOOD SAMPLING; COMORBIDITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINES; CONFIDENCE INTERVALS; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; PIRENZEPINE; RITONAVIR;

EID: 0036325312     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200208000-00006     Document Type: Article

References (19)

1. Schizophrenia and HIV
2. Practice guideline for the treatment of patients with HIV/AIDS: Work group on HIV/AIDS
3. Use of hospital services by AIDS patients with psychiatric illness
4. Olanzapine: Pharmacokinetic and pharmacodynamic profile
5. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanisms
6. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease: The Advanced HIV Disease Ritonavir Study Group
7. Dual protease inhibitor therapy in HIV infected patients: Pharmacologic rationale and clinical benefits
8. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
9. Sample size calculations for clinical pharmacology studies
10. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline
11. Effect of ritonavir of CYP1A2, 2C19, and 2E1 activities in vivo
12. Analysis of olanzapine in human plasma utilizing reversed-phase high performance liquid chromatography with electrochemical detection
13. Rapid and sensitive high performance liquid chromatographic method for the determination of ritonavir in human plasma
14. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients
15. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American olanzapine trial
16. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
17. Alprazolamritonavir interaction: Implications for product labeling
18. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir